Avalo Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.83 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-0.98 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-2.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-1.92 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $249.00K | $-2.83 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | After market close | – | – | – |
Press releases
Announcements Avalo Therapeutics filed with the SEC
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Therapeutics Purchases Optional Milestone Buyout
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW January 2026 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1
Results of operations · Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Executive or director change · Other events · EX-99.1 to Form 8-K
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
June 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
May 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Executive or director change · Other events · EX-99.1 to Form 8-K
Avalo Reports 2024 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
January 2025 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
December 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Other events · EX-99.1 to Form 8-K
November 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) EXHIBIT 99.2
Other events · EX-99.2 to Form 8-K
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Other events · EX-99.1 to Form 8-K
October 2024 Corporate Presentation Avalo Therapeutics, Inc. (AVTX) EXHIBIT 99.2
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Other events · EX-99.1 to Form 8-K
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Reports 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K